National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 55565-55566 [E9-25878]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
concerning individuals associated with
the research programs at NCTR.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Margaret
Miller (Contact Person) at least 7 days
in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: October 23, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–25941 Filed 10–27–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
erowe on DSK5CLS3C1PROD with NOTICES
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Clinical Trials and
Translational Research Advisory
Committee, November 4, 2009, 8 a.m. to
November 4, 2009, 5 p.m., National
Institutes of Health, Building 31, 31
Center Drive, Bethesda, MD 20892,
which was published in the Federal
Register on August 31, 2009,
74FR44860.
This meeting is amended to adjust the
end time to 4 p.m. The meeting is open
to the public.
Dated: October 22, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25907 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
VerDate Nov<24>2008
15:34 Oct 27, 2009
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; ‘‘R13 Conference Grants.’’
Date: November 20, 2009.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Yong Gao, PhD, Scientific
Review Officer, Scientific Review Program,
DEA/NIAID/NIH/DHHS, Room 2217, 6700B
Rockledge Drive, Bethesda, MD 20892–7616,
301–443–8115, gaol2@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25902 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
55565
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Biology of
Neuroendocrine Peptides.
Date: December 1, 2009.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, ls38z@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25879 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
E:\FR\FM\28OCN1.SGM
28OCN1
55566
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
Emphasis Panel; Ancillary Studies in
Immunomodulation Clinical Trials.
Date: November 17, 2009.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817 (Telephone Conference
Call).
Contact Person: Paul A. Amstad, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
402–7098, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25878 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Meeting
erowe on DSK5CLS3C1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of an Interagency Autism
Coordinating Committee (IACC)
meeting.
The purpose of the IACC meeting is
to discuss recommendations for the
annual update of the IACC Strategic
Plan for Autism Spectrum Disorders
Research. The meeting will be open to
the public and will be accessible by
webcast and conference call.
Name of Committee: Interagency Autism
Coordinating Committee (IACC).
Type of Meeting: Open Full Committee
Meeting.
Date: November 10, 2009.
Time: 9 a.m. to 5 p.m.* Eastern Time—*
Approximate end time.
Agenda: To discuss recommendations for
the annual update of the IACC Strategic Plan
for Autism Spectrum Disorder Research.
Place: National Institute of Mental Health,
6001 Executive Boulevard, Neuroscience
Center, Conference Rooms A1/A2, Rockville,
MD 20852.
Webcast Live: https://videocast.nih.gov/.
Conference Call Access:
Dial: 888–577–8995.
Access code: 1991506.
Cost: The meeting is free and open to the
public.
Registration: Pre-registration is
recommended to expedite check-in. Seating
VerDate Nov<24>2008
15:34 Oct 27, 2009
Jkt 220001
is limited to room capacity and on a first
come, first served basis. Online preregistration will be available. Please visit the
IACC Web site for pre-registration
information: https://www.iacc.hhs.gov.
Access: Metro accessible—Red Line—
White Flint Metro Station.
Contact Person: Ms. Lina Perez, Office of
Autism Research Coordination, Office of the
Director, National Institute of Mental Health,
NIH, 6001 Executive Boulevard, NSC, Room
8200, Bethesda, MD 20892–9669, Phone:
301–443–6040, E-mail:
IACCPublicInquiries@mail.nih.gov.
Please Note: Any member of the public
interested in presenting oral comments to the
Committee must notify the Contact Person
listed on this notice at least 5 days in
advance of the meeting. Interested
individuals and representatives of
organizations must submit a letter of intent,
a brief description of the organization
represented, and a written/electronic copy of
the oral presentation/statement by 5 p.m. ET,
November 6, 2009. A printed/electronic copy
of the comment/statement provided by the
deadline is required prior to the oral
presentation; the document will become a
part of the public record. Only one
representative of an organization will be
allowed to present oral comments and
presentations will be limited to three to five
minutes per speaker, depending on number
of speakers to be accommodated within the
allotted time. Speakers will be assigned a
time to speak in order of the date and time
when their request to speak is received, along
with the required written statement
submitted in advance of the meeting by
November 6 at 5 p.m. ET.
In addition, any interested person may
submit written comments to the IACC prior
to the meeting by sending the statement to
the Contact Person listed on this notice at
least by 5 p.m. ET, November 6, 2009. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person. All written statements
received by the deadline for both oral and
written public comment will be provided to
the IACC for their consideration.
The meeting will be open to the public
through a conference call phone number and
webcast live on the Internet. Individuals who
participate in person or by using these
electronic services and who need special
assistance, such as captioning of the
conference call or other reasonable
accommodations, should submit a request at
least 7 days prior to the meeting.
As a part of security procedures, attendees
should be prepared to present a photo ID at
the meeting registration desk during the
check-in process. Pre-registration is
recommended. Seating will be limited to the
room capacity and seats will be on a first
come, first served basis, with expedited
check-in for those who are pre-registered.
Members of the public who participate
using the conference call phone number will
be able to listen to the meeting but will not
be heard.
To access the webcast live on the Internet
the following computer capabilities are
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
required: (A) Internet Explorer 5.0 or later,
Netscape Navigator 6.0 or later or Mozilla
Firefox 1.0 or later; (B) Windows® 2000, XP
Home, XP Pro, 2003 Server or Vista; (C)
Stable 56k, cable modem, ISDN, DSL or
better Internet connection; (D) Minimum of
Pentium 400 with 256 MB of RAM
(Recommended); (E) Java Virtual Machine
enabled (Recommended)
Meeting schedule subject to change.
This meeting is being published less than
15 days prior to the meeting due to the
timing limitations for completing the
updating of the Annual Strategic Plan for
Autism Spectrum Disorder Research.
Information about the IACC is available on
the Web site: https://www.iacc.hhs.gov.
Dated: October 22, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25991 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Child Health and Human Development
Special Emphasis Panel, November 13,
2009, 10 a.m. to November 13, 2009, 4
p.m., National Institutes of Health, 6100
Executive Boulevard, Room 5B01,
Rockville, MD, 20852 which was
published in the Federal Register on
October 16, 2009, 74 FR 53278.
The meeting date and time have been
changed to November 16, 2009, 9 a.m.
to November 16, 2009, 12 p.m.
The meeting is closed to the public.
Dated: October 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25955 Filed 10–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC)—Health Disparities
Subcommittee (HDS)
Correction: This notice was published
in the Federal Register on October 15,
2009, Volume 74, Number 198, Page
E:\FR\FM\28OCN1.SGM
28OCN1
]]>Agencies
[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Pages 55565-55566]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25878]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special
[[Page 55566]]
Emphasis Panel; Ancillary Studies in Immunomodulation Clinical
Trials.
Date: November 17, 2009.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge 6700, 6700B
Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Paul A. Amstad, PhD, Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities, NIAID/
NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616,
301-402-7098, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-25878 Filed 10-27-09; 8:45 am]
BILLING CODE 4140-01-P
